Global Orally Disintegrating Tablet Market by Type (Fast-Disintegrating Tablets, Immediate-Release Tablets), by Drug Class (Anti-Psychotics, Anti-Epileptics, Anti-Migraines, Anti-Allergies), by End-Use Industry (Hospitals, Clinics, Home Care); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Orally Disintegrating Tablet Market was valued at USD 16.8 Billion in 2024-e and will surpass USD 30.1 Billion by 2030; growing at a CAGR of 10.1% during 2025 - 2030.  

The Orally Disintegrating Tablet (ODT) Market is gaining prominence due to the increasing demand for convenient and patient-friendly drug delivery systems. ODTs dissolve quickly in the mouth without the need for water, making them an ideal solution for patients with difficulty swallowing, such as the elderly and pediatric populations. These tablets are extensively used for treating conditions that require immediate drug action, including neurological disorders, migraines, and allergies. The market is driven by technological advancements, expanding applications across drug classes, and growing acceptance among healthcare providers and patients alike.

Fast-Disintegrating Tablets Segment Is Largest Owing to Broad Patient Acceptance

The fast-disintegrating tablets segment holds the largest share of the ODT market, primarily due to their wide applicability and broad acceptance among patients. These tablets dissolve rapidly in the mouth, typically within seconds, offering convenience for patients who struggle with traditional oral dosage forms. Fast-disintegrating tablets are particularly beneficial for conditions requiring rapid onset of action, such as migraines and acute allergic reactions, which makes them a preferred choice for both patients and healthcare providers.

The growth of this segment is further fueled by innovations in formulation technologies that enhance the stability, taste, and bioavailability of drugs in ODT form. As pharmaceutical companies continue to expand their product portfolios to include fast-disintegrating tablets for various therapeutic areas, this segment is expected to maintain its dominance in the market.

Anti-Psychotics Segment Is Fastest Growing Owing to Rising Neurological Disorder Cases

The anti-psychotics drug class is the fastest-growing segment in the ODT market, driven by the increasing prevalence of neurological and psychiatric disorders such as schizophrenia and bipolar disorder. Orally disintegrating tablets provide a significant advantage in this therapeutic area by improving medication adherence among patients who may have difficulty swallowing pills or are non-compliant with traditional dosage forms.

The rapid onset of action offered by ODTs ensures timely therapeutic effects, which is critical for managing acute episodes of psychosis. Furthermore, advancements in drug formulation have enabled the development of ODTs that mask the bitter taste of anti-psychotic medications, improving patient acceptability. With the growing awareness of mental health issues and the need for patient-centric drug delivery systems, the anti-psychotics segment is poised for substantial growth.

Home Care Segment Is Largest End-Use Industry Owing to Growing Preference for At-Home Treatment

The home care segment is the largest end-use industry in the ODT market, driven by the rising trend of at-home treatment for chronic and acute conditions. Orally disintegrating tablets are highly convenient for home use, as they eliminate the need for water or additional assistance during administration. This feature makes them particularly suitable for elderly patients, children, and individuals with limited mobility.

The increasing availability of ODTs across various therapeutic areas, coupled with growing consumer preference for self-administered medications, is boosting the demand for ODTs in home care settings. The segment's dominance is also supported by advancements in telemedicine and online pharmacies, which make it easier for patients to access these innovative drug delivery solutions.

North America Is Largest Region Owing to High Adoption of Advanced Drug Delivery Systems

North America is the largest regional market for orally disintegrating tablets, attributed to the high adoption of advanced drug delivery systems and the strong presence of leading pharmaceutical companies. The region's well-established healthcare infrastructure and favorable reimbursement policies encourage the development and use of ODTs for various therapeutic indications.

The growing prevalence of neurological and chronic disorders in the region, along with the increasing focus on improving medication adherence, further drives the demand for ODTs. Additionally, North America benefits from a proactive regulatory environment that supports the approval and commercialization of innovative drug delivery technologies, solidifying its position as the largest regional market for ODTs.

Competitive Landscape and Key Players

The Orally Disintegrating Tablet Market is characterized by intense competition, with major players such as Pfizer, Novartis, Merck & Co., and Teva Pharmaceuticals leading the market. These companies are focused on developing innovative ODT formulations that address unmet medical needs and improve patient outcomes.

The competitive landscape is also marked by strategic partnerships, mergers, and acquisitions aimed at expanding product portfolios and geographic reach. Additionally, advancements in formulation technologies, such as taste-masking and rapid disintegration, are enabling key players to differentiate their products in a crowded marketplace. As the demand for patient-friendly drug delivery systems continues to rise, the market is expected to witness sustained growth driven by innovation and increasing consumer acceptance.

Recent Developments:

• Pfizer Inc. launched a new fast-dissolving tablet formulation for pain relief targeting both pediatric and geriatric patients.
• Teva Pharmaceutical Industries Ltd. announced the acquisition of a manufacturing plant focused on ODT production in Europe.
• GlaxoSmithKline unveiled an ODT version of a popular allergy medication to improve compliance in younger patients.
• Sun Pharmaceutical Industries Ltd. received FDA approval for an orally disintegrating antiepileptic drug targeting the US market.
• Novartis AG introduced a new ODT for migraine relief, claiming faster onset of action compared to traditional tablets.

List of Leading Companies:

• Pfizer Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (Viatris)
• Johnson & Johnson
• Novartis AG
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• Zydus Cadila
• Torrent Pharmaceuticals Ltd.

Report Scope: